Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for early diaphragmatic dysfunction after uni-port thoracoscopic lobectomy
ChiCTR2400086230Phase 4Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- Jun 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Diaphragmatic dysfunction (DD) and postoperative respiratory complications (PRC) comparing Sugammadex group with Neostigmine + atropine group (2 arms). Primary endpoint: Excursion of diaphragmatic dysfunction. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
Sugammadexneostigmine
03
Conditions
Diaphragmatic dysfunction (DD)postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2400086230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086230.